Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
News about Charles River Laboratories International, Inc. (NYSE: CRL) focuses on its role in research and development in biotechnology and its activities as a contract research and manufacturing partner to pharmaceutical, biotechnology, government, and academic clients. Company updates often highlight how Charles River’s research models, discovery and safety assessment services, and manufacturing solutions support the discovery, early-stage development, and safe manufacture of new therapies.
Investors and industry followers can expect frequent news on strategic transactions and partnerships. Recent announcements include planned acquisitions such as K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory-required biomedical, pharmaceutical, and toxicological research, and PathoQuest SAS, a provider of next-generation sequencing solutions for manufacturing quality-control testing. The company also reports collaborations, for example with The Francis Crick Institute on antibody-drug conjugate discovery and with X-Chem, Inc. to expand hit identification capabilities using DNA-encoded library technology.
Charles River’s news flow also covers scientific and operational initiatives. The company has announced the creation of a Scientific Advisory Board led by Dr. Namandjé N. Bumpus to advance New Approach Methodologies (NAMs) and reduce reliance on animal testing, as well as the expansion of its Cell & Gene Therapy Incubator Program to support early-stage advanced therapy developers and enabling technology companies. Updates on its strategic review, portfolio refinement, restructuring initiatives, and capital deployment plans provide additional context on long-term positioning and financial priorities.
Governance and leadership developments are another recurring theme, such as the planned CEO succession and the appointment of a Chief Scientific and Innovation Officer. Earnings releases and conference presentations offer insight into demand trends across the Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments. For readers tracking CRL, this news page brings together these earnings updates, transaction announcements, scientific collaborations, and strategic milestones in one place.
Charles River Laboratories (NYSE: CRL) will present at two investor conferences in March 2026: TD Cowen on March 3, 2026 at 9:50 a.m. ET and Barclays on March 10, 2026 at 10:00 a.m. ET. Management will discuss strategic focus, business developments, and recent trends.
A live webcast link will be posted on the company's Investor Relations website at ir.criver.com, and replays will remain available for at least two weeks after each presentation.
Charles River Laboratories (NYSE: CRL) signed definitive agreements to divest its CDMO and Cell Solutions businesses to GI Partners and certain European Discovery Services assets to IQVIA for approximately $145 million in cash plus up to $10 million in additional payments. The deals cover sites in the US, UK, and Europe and generated combined 2025 revenue cited at $143 million (CDMO and Cell Solutions) and $144 million (divested discovery capabilities). Both transactions are expected to close in Q2 2026, subject to customary conditions. The company updated 2026 guidance, estimating slightly more than $200 million lower reported revenue, a >50-basis-point reduction to organic growth, at least 100 basis points of incremental non-GAAP operating margin improvement, and roughly $0.10 accretion to non-GAAP EPS for the partial year.
Charles River Laboratories (NYSE: CRL) announced two senior executive appointments: Glenn G. Coleman will become Corporate Executive Vice President and Chief Financial Officer effective April 6, 2026, and Kerry Dailey will become Corporate Senior Vice President and Chief Legal Officer effective March 30, 2026.
Dailey will lead a newly consolidated legal, compliance, communications, government relations, security, and ESG function; Matthew Daniel will support transition through July 1, 2026, then depart.
Charles River Laboratories (NYSE: CRL) reported Q4 2025 revenue of $994.2M and full-year 2025 revenue of $4.02B. GAAP EPS was a loss of $(5.62) in Q4 and $(2.91) for 2025; non-GAAP EPS was $2.39 in Q4 and $10.28 for 2025. The quarter included substantial intangible and goodwill impairments totaling $376.0M. Management provided 2026 guidance with non-GAAP EPS of $10.70–$11.20 and GAAP EPS of $6.30–$6.80, and expects a return to organic revenue growth in H2 2026.
Charles River Laboratories (NYSE: CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18, 2026, before the market opens. A conference call to discuss the results and guidance is scheduled for February 18, 2026 at 8:30 a.m. ET. Investors can listen to a live webcast and access a replay via the company’s Investor Relations website at ir.criver.com. The announcement covers timing and access only; financial details will be provided at the release and call.
Charles River (NYSE: CRL) and Gazi University Faculty of Medicine announced a CDMO collaboration on January 21, 2026 to support rare disease gene therapy research. Charles River will supply off-the-shelf, research-grade AAV plasmid DNA produced with animal component-free methods and provided royalty-free for early-stage programs. The collaboration targets Hyperphosphatemic tumoral calcinosis (HTC), with Gazi University identifying GALNT3 as the causal gene. The agreement aims to accelerate in vitro efficacy studies and lower early development costs.
Charles River Laboratories (NYSE: CRL) announced two planned acquisitions, a senior scientific hire, and a 2026 outlook update at the J.P. Morgan Healthcare Conference. The company agreed to buy K.F. (Cambodia) Ltd. for approximately $510.0 million, expected to be accretive to non-GAAP EPS by ~$0.25 in 2026 and ~$0.60 in 2027. Charles River exercised its option to acquire the remaining 79% of PathoQuest for ~€51.6 million (~$60M); PathoQuest revenue is expected to be ~$15–20M in 2026. Dr. Namandjé N. Bumpus joins as SVP, Chief Scientific and Innovation Officer. Operational notes: DSA net book-to-bill ~1.1x in Q4 2025; 2026 organic revenue growth guidance top end expected to be at least flat; FX to add 100–150 bps to reported growth.
Charles River Laboratories (NYSE: CRL) announced that James C. Foster will retire effective May 5, 2026 at the conclusion of the 2026 Annual Meeting and the Board has unanimously appointed Birgit Girshick, current EVP and COO, as CEO effective in May 2026.
Mr. Foster will remain on the Board as a non-executive director and Martin Mackay will become independent Chair. Foster led Charles River for 30+ years, oversaw 50+ acquisitions, and helped grow revenue from $307M in 2000 to $4.0B in 2024; the company reports working on >80% of FDA-approved drugs since 2017. Girshick has 35+ years at the company and has served as COO since 2021.
Charles River (NYSE: CRL) announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP) on December 11, 2025, completing its 2025 global cohort onboarding and opening applications for 2026.
The six-member cohort includes four advanced therapy developers (CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics, Kopra Bio) and two enabling technology companies (Grace, HTLab Biowerkli). Participants receive tailored mentorship, regulatory and quality consults, training, and preferential access to Charles River’s global discovery, development, and manufacturing network.
Notable program details: Jaan aims to start clinical testing in 2027, InterAct focuses on AAV8 gene therapy for breast cancer liver metastases, and Kopra has a first development candidate targeting glioblastoma.
Charles River Laboratories (NYSE: CRL) will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025 at 10:00 a.m. ET. Management will provide an overview of the company's strategic focus, business developments, and recent trends. A live webcast will be available via a link posted on the Investor Relations website at ir.criver.com, and a replay will be accessible on the same site for at least two weeks after the presentation.